{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-24-000039","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.674230+00:00","generated_at":"2026-06-05T19:19:22.342997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Guardant Health Q4 rev $155.1M (+22% YoY); GAAP net loss $187.0M incl $83.4M legal accrual; 2024 guidance $655-670M","bullets":["Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.","GAAP net loss Q4 $187.0M ($1.58 per share) vs $139.9M ($1.36) prior year, including $83.4M non-recurring legal accrual.","Clinical test volume 46,400 in Q4 (+29% YoY); full year 172,900 (+39% YoY).","2024 revenue guidance $655-670M (16-19% growth); non-GAAP op expense $740-750M; free cash flow -$320 to -$330M.","Cash and marketable securities $1.2B at year-end; Shield PMA submission under FDA review, expect FDA approval and launch in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-24-000039","json":"https://secwatch.observer/filing/0001576280-24-000039.json","markdown":"https://secwatch.observer/filing/0001576280-24-000039.md","text":"https://secwatch.observer/filing/0001576280-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/gh-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:19:22.342997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30aabde8593cd381a8c7e3e7f687a8ef0107fe73","claim":"Guardant Health, Inc. updated its full year 2024 guidance (initiated).","evidence_excerpt":"Expects full year 2024 revenue to be in the range of $655 to $670 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"910eb8815ee7cd83ea4142dbd49c58166eddd1d8","claim":"Guardant Health, Inc. reported the fourth quarter of 2023 results: revenue $155.1 million, net income Net loss was $187.0 million, EPS Net loss per share was $1.58.","evidence_excerpt":"leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Revenue of $155.1 million for the fourth quarter of 2023, an increase of 22% over the fourth quarter of 2022 • Reported 46,400 tests to clinical customers and 9,500 tests to biopharmaceutical customers in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$155.1 million"},{"label":"Net income","value":"Net loss was $187.0 million"},{"label":"EPS","value":"Net loss per share was $1.58"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a68d38cee9f3667b79e416a2cbace8512f025497","claim":"Guardant Health, Inc. reported the full year ended December 31, 2023 results: revenue $563.9 million. Guidance reaffirmed.","evidence_excerpt":"Revenue was $563.9 million for 2023, a 25% increase from $449.5 million for the corresponding prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000039/0001576280-24-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$563.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}